These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17390569)

  • 21. Stimulant medications and attention deficit-hyperactivity disorder.
    Cohen AL; Jhung MA; Budnitz DS
    N Engl J Med; 2006 May; 354(21):2294-5. PubMed ID: 16723627
    [No Abstract]   [Full Text] [Related]  

  • 22. [Sympathomimetics in ADHD. Cardiovascular risks, FDA warns].
    Ostman-Smith I; Dellborg M
    Lakartidningen; 2007 Apr 25-May 1; 104(17):1307. PubMed ID: 17547274
    [No Abstract]   [Full Text] [Related]  

  • 23. Adderall: the newest available option in ADHD.
    Adv Nurse Pract; 1997 Jun; 5(6):73-4. PubMed ID: 9459934
    [No Abstract]   [Full Text] [Related]  

  • 24. Adderall in the land of Oz.
    Hammerschlag C
    Caring; 2013; 32(2):55. PubMed ID: 23697076
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on adult attention-deficit/hyperactivity disorder.
    Hammerness P; Surman C; Miller K
    Curr Neurol Neurosci Rep; 2008 Nov; 8(6):484-9. PubMed ID: 18957185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attention-deficit/hyperactivity disorder stimulant medication reaction masquerading as chronic cough.
    Leibel S; Bloomberg G
    Ann Allergy Asthma Immunol; 2013 Aug; 111(2):82-3. PubMed ID: 23886223
    [No Abstract]   [Full Text] [Related]  

  • 27. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.
    Hammerness PG; Surman CB; Chilton A
    Curr Psychiatry Rep; 2011 Oct; 13(5):357-63. PubMed ID: 21698412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Safety of drugs to treat attention deficit disorder with hyperactivity].
    Péluchon R
    Soins Pediatr Pueric; 2012; (268):9. PubMed ID: 23074795
    [No Abstract]   [Full Text] [Related]  

  • 30. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.
    Torres AR; Whitney J; Gonzalez-Heydrich J
    Epilepsy Behav; 2008 Feb; 12(2):217-33. PubMed ID: 18065271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemoline (Cylert): market withdrawal.
    Hogan V
    CMAJ; 2000 Jan; 162(1):106, 110. PubMed ID: 11216184
    [No Abstract]   [Full Text] [Related]  

  • 32. US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.
    Eggertson L
    CMAJ; 2005 Mar; 172(7):865. PubMed ID: 15758187
    [No Abstract]   [Full Text] [Related]  

  • 33. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed amphetamine salts extended release for the treatment of ADHD.
    Biederman J
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):5. PubMed ID: 16344840
    [No Abstract]   [Full Text] [Related]  

  • 35. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 36. Response to 'Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy'.
    Paterson R
    Aust N Z J Psychiatry; 2000 Oct; 34(5):874-5. PubMed ID: 11037381
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
    Vetter VL; Elia J; Erickson C; Berger S; Blum N; Uzark K; Webb CL; ;
    Circulation; 2008 May; 117(18):2407-23. PubMed ID: 18427125
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.
    Weisler RH; Biederman J; Spencer TJ; Wilens TE
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):35-43. PubMed ID: 16344839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe weight loss induced by Adderall in a child with ADHD.
    Kalikow KT; Blumencranz H
    J Child Adolesc Psychopharmacol; 1996; 6(1):81-2. PubMed ID: 9231303
    [No Abstract]   [Full Text] [Related]  

  • 40. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV; Wigal SB; Hodgkins P
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.